Отпорност на антибиотици особено од грам-негативни бактерии речиси создаде ситуација слична на криза. Новиот антибиотик Zosurabalpin (RG6006) покажува ветувања. Утврдено е дека е ефикасен против грам-негативни бактерии CRAB отпорни на лекови во претклиничките студии.
Antimicrobial resistance (Амр), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of антибиотици to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of антибиотик отпор.
Ацинетобактер баумани is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available антибиотици. There is an urgent need for an effective антибиотик against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective антибиотик. A progress towards this goal has been reported.
Scientists have identified a novel class of антибиотици namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
Зосурабалпин (RG6006) е антибиотик candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-клинички trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame антибиотик-resistance mechanism of CARB suggesting Зосурабалпин има потенцијал.
Hence, human клинички trials have been initiated to check for safety and efficacy Зосурабалпин во лекувањето на инвазивни инфекции предизвикани од РАК.
***
Референци:
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel антибиотик class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- Хаусер С., и сор 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Клинички Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
